Smallcap holds up to 12 small caps above $200M trading at $1 or more. Selection follows the model's conviction in each name.
Strategy
Equal capital goes into every recommendation. Recommendations are published a few hours before the open and placed as market orders, so buys and sells fill at the opening price. There is no maximum holding period: a position exits when the model no longer selects it or when the stop is hit. Every position carries a 25% stop-loss: if the price touches it during the day, the position is sold there, at 75% of its entry price. Reported returns are measured from those opening prices and include every stop-loss exit.
Industry:Medical - Healthcare Information Services
Market Cap:$4.56B
Analysts Target:-6%
Analysts Rating:2.2/5
ForecastQ Daily Probabilities
42.1%
35.8%
26.6%
Recent News & Events
DMACPOSITIVENov 24, 2026
Clinical Data Event / KOL Webinar
Nov 24 KOL webinar to include new FGR cohort data
DiaMedica rescheduled its FGR key opinion leader webinar to Nov 24, 2026, expanding it to include preliminary interim topline results from the second cohort of the investigator-sponsored Phase 2 early-onset FGR trial alongside first-cohort data. Positive safety/efficacy signals could support the preeclampsia/FGR franchise narrative and lift shares, while weak or ambiguous data could weigh on sentiment.
DiaMedica will release Q3 2026 financial results after market close on Nov 12, 2026, with a business update call on Nov 13 at 8:00 AM ET. Consensus expects a net loss of about -$0.21 per share with no product revenue; focus will be on R&D spend trends, cash balance (~$43.5M at Q2) and runway guidance into 2027, plus any ReMEDy2 timeline commentary. Quarterly prints have historically produced contained moves for this pre-revenue biotech, so impact is likely modest unless cash burn or timelines surprise.
Rubrik announced it will report Q3 fiscal 2027 results after market close on Nov 30, 2026, with a conference call at 5:00 pm ET. Per commentary, near-term share moves hinge on net new subscription ARR at this print, making it the key short-term catalyst.
Baron letter cites 27% ARR growth and raised FY guidance
Baron's Q3 2026 investor letter disclosed that Netskope contributed 0.93% to returns at the Baron SMID Cap ETF, citing 27% year-over-year ARR growth, revenue growth of 29%, an 11-point operating margin improvement, and a raised full-year guidance. Institutional endorsement plus fundamental momentum narrative can attract momentum and fund flows in the near term.
NTSK traded up about 5.18% intraday to $22.55, holding above its weekly (~$22.01) and quarterly (~$18.49) moving averages after consolidating in the $21-22 range. Technical strength and volume expansion raise the probability of a retest of the late-October high near $26.52, though weakening MACD momentum is a caveat.
Analysts downgrade Aeromexico outlook despite court ruling
Reports indicate analysts downgraded the outlook for Aeromexico around Nov. 11, 2026, even as the company won a court ruling. Downgrades can pressure the stock via reduced institutional demand and negative sentiment; the shares were noted as down ~12% over the prior month.
Renewed momentum in the AI complex, following stronger-than-expected results from AI infrastructure names, drove a ~7.5% single-day gain on Nov 11, pushing FROG through its prior 52-week high of $108.59 to around $111.31. The breakout removes a near-term technical hurdle and reflects continued follow-through from the Q3 beat-and-raise, though the extended move raises pullback risk.
Expanded AWS Cyber Recovery and ABR General Availability
Rubrik unveiled advanced cyber investigation/recovery capabilities for AWS workloads and announced GA of Autonomous Business Recovery for AWS Cloud Applications, extended to EKS, ECR, Lambda, and S3. Positive for medium-term adoption but likely feeds into future quarters rather than near-term numbers.
Google BigQuery and Cloud Storage Data Protection Extension
Rubrik extended Google Cloud data protection to Google Cloud Storage and announced GA of agentless, immutable backup for Google BigQuery. Broadens platform coverage; incremental positive sentiment but limited near-term financial impact.
Rubrik introduced cyber recovery capabilities for Microsoft Azure DevOps and GitHub, including anomaly detection, blast radius investigation, and surgical recovery. Expands addressable market; positive but medium-term adoption driver.
Management outlines GPCR pipeline at Guggenheim conference
At the Guggenheim Healthcare Innovation Conference, Septerna management highlighted a pipeline built entirely around GPCRs and reiterated sufficient cash to fund operations, reinforcing the discovery-platform story. Conference commentary is a modest sentiment support but unlikely to be a major standalone price driver.
RBC lifts NTSK target to $23, maintains Outperform
Royal Bank of Canada raised its price target on Netskope from $20 to $23 while keeping an "outperform" rating, implying roughly 8% upside from the prior close. Sell-side target revisions of this kind typically draw incremental buyers and reinforce the "Moderate Buy" consensus (average target ~$19.82), supporting near-term sentiment.
Septerna reported a Q3 2026 net loss of $26.6M (-$0.57/share) versus a $0.18 profit a year earlier, wider than the ~$0.42 loss consensus, with revenue of $18.88M below the ~$20.78M estimate. R&D spending jumped over 50% YoY to $36.6M, widening the loss and triggering a post-earnings pullback of roughly 2.2%.
Septerna reiterated that its ongoing Phase 1 SAD/MAD trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, will report data in Q1 2027. The reaffirmed catalyst timeline keeps investor focus on the upcoming readout, though the event itself falls outside the immediate two-week window.
Novo Nordisk collaboration advances; $13M milestones achieved
Under the July 2025 Novo Nordisk collaboration, Novo assumed responsibility for a Septerna-delivered development candidate and initiated IND-enabling toxicology studies, with Septerna having achieved $13M in research milestones to date. The progress validates the platform and provides non-dilutive revenue, a mild positive for sentiment.
CEO David J. Wilson bought 32,631 shares (~$551,349) at an average of $16.90 on Nov. 5, not under a pre-arranged plan, per a Form 4 filing. Open-market CEO buying shortly after a strong earnings beat signals insider confidence and can support positive short-term sentiment.
TD Cowen raises PT to $36; consensus target rises to $29
TD Cowen maintained Buy and lifted its price target to $36 from $31, while the average 12-month target rose to $29 from $25.86 with a Buy consensus (five Buy, two Hold). Upward estimate/target revisions following the Q3 beat can drive near-term buying interest.
RCEL reported Q3 EPS of -$0.20 vs -$0.24 consensus and revenue of $26.1M vs $22.35M consensus (53% YoY growth), and raised FY2026 revenue guidance to $92-94M from $86-89M while reaffirming Q4 cash flow breakeven. The beat-and-raise supports positive near-term sentiment, though the new FY range sits well below the $121.2M analyst consensus, which could temper enthusiasm.
CMS finalizes national RECELL physician payment, simplified codes
CMS finalized national physician RVU valuations and a simplified four-code CPT structure for RECELL SCSA procedures effective January 1, 2027, replacing regional MAC valuations and an eight-code system. Management frames this as improving payment predictability and supporting broader RECELL adoption, a positive structural catalyst for the stock.
The Q3 Form 10-Q no longer carries a going-concern qualification after improved operating performance and liquidity, and the company drew the remaining $10M Perceptive Advisors tranche (total borrowings $60M) after hitting the $85M TTM revenue milestone. Removal of the going-concern doubt and strengthened liquidity reduce perceived financial risk near term.
PermeaDerm I met its primary endpoint, showing comparable clinical outcomes to allograft with 70% lower product cost and 95.7% less preparation time. Positive data supports the commercial case for PermeaDerm and adds a potential incremental growth driver, a modest positive for sentiment.
Korro reported Q3 2026 results on Nov 5, 2026 with a net loss of $17.5M and cash of $124.8M, funding operations into H2 2028. The update highlighted KRRO-121 first-in-human dosing, FDA rare pediatric disease designation, and best-in-class KRRO-111 preclinical data, providing a balanced mix of pipeline progress against the Novo termination overhang.
FDA Rare Pediatric Disease Designation for KRRO-121
Korro received FDA rare pediatric disease designation for KRRO-121 in UCDs, which may confer priority review voucher eligibility upon approval and highlights regulatory recognition of the program. This is a modest positive catalyst supporting the KRRO-121 development path.
JFrog reported Q3 2026 revenue of $179.2M (+31% YoY) and non-GAAP EPS of $0.32, beating consensus of ~$165.8M and $0.23. Cloud revenue grew 60% to $101.5M, NDR rose to 124%, and FY2026 guidance of $680-682M revenue and $1.14-1.16 EPS came in well above consensus (~$650.7M and $0.98). The beat-and-raise drove a sharp positive reaction, with shares jumping over 20% after hours and in the following session.
On the Q3 2026 earnings call, management disclosed a $76M multiyear SaaS agreement with a leading global telecommunications company, representing 167% growth in cloud data consumption versus the prior commitment, with expansion into AI security and governance. The large deal size and expansion signal durable enterprise demand, reinforcing the positive post-earnings narrative.
Netskope sets FQ3 2027 earnings for December 2, 2026
Netskope will report fiscal third quarter 2027 results (quarter ended October 31, 2026) after the close on December 2, 2026, with a call at 5:00 pm ET. The confirmed date focuses investor attention on the print; company guidance is for a Q3 loss of $0.04 to $0.03 per share, so positioning and any pre-earnings estimate revisions are the near-term drivers.
Q3 2026 results beat; full-year ACV and drug discovery guidance raised
Schrödinger reported Q3 2026 total revenue of $64.5M (+19% YoY), ACV of $44.7M (+17%), and drug discovery revenue of $24.2M, then raised FY2026 ACV guidance to $222–232M and drug discovery revenue to $75–85M. The beat-and-raise supports positive near-term sentiment and underpins analyst target increases.
Novartis deal amended; potential milestones raised to $1.424B
Schrödinger amended its Novartis collaboration, replacing programs and increasing potential milestone payments to $1.424B; Bristol Myers Squibb also adopted its Bunsen platform. Expanded partnership economics reinforce the platform's commercial validation and support sentiment.
8-K corrects ASH abstract on SGR-1505 combination study
Schrödinger filed an 8-K correcting its ASH abstract, clarifying it has not initiated a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities to continue development. The correction could temper expectations around the MALT1 program ahead of the December data readout.
SGR-1505 Phase 1 data slated for ASH oral session Dec 12–15
Updated Phase 1 data for zilemaltib (SGR-1505) in relapsed/refractory B-cell malignancies will be presented in an oral session at the ASH Annual Meeting (Dec 12–15, 2026), with dose escalation complete. This is a near-term binary catalyst that could move shares depending on safety/efficacy results.
SEP-204 selected as TSHR NAM development candidate
Septerna announced selection of oral SEP-204 as its TSHR negative allosteric modulator development candidate for Graves' disease and thyroid eye disease, with preclinical data presented at the ATA annual meeting showing restored T4 levels and reduced proptosis in animal models. The company plans to initiate a Phase 1 trial in Q1 2027, expanding the pipeline and supporting the longer-term narrative.
Aeromexico reported October 2026 ASMs up 4.5% and RPMs up 5.9% year over year, with load factor rising 1.1 p.p. to 88.2%. Demand outpacing capacity signals solid network strength into the year-end peak season, a modest positive for revenue expectations.
Teknova reported Q3 2026 revenue of $12.7M, up 22% YoY and ahead of the ~$11.7M consensus, with EPS of -$0.06 beating the -$0.07 estimate. The company raised FY2026 revenue guidance to $46-48M and reaffirmed Free Cash Outflow under $8M, a positive near-term signal likely to sustain buying interest.
Profitability still distant; EBITDA breakeven needs $52-57M revenue
Management indicated the company remains unprofitable with a $3.5M Q3 net loss and that adjusted EBITDA positivity is not expected until annualized revenue reaches $52-57M, above current guidance. This tempers enthusiasm and may cap near-term upside.
Launch of Fill-Tek Dispensing System expands platform
Teknova launched the Fill-Tek Dispensing System, adding flexibility for custom single-use bag sizes and fill volumes across RUO, RUO+, and GMP grades. The product expansion supports the growth narrative but is unlikely to be a major standalone near-term price driver.
Novo Nordisk Terminates Korro Collaboration for Convenience
Korro received written notice on Nov 3, 2026 that Novo Nordisk elected to terminate the September 2024 research collaboration and license agreement for convenience, effective February 1, 2027. Novo Nordisk did not nominate a second target and no milestones were earned; the loss of future milestone/royalty optionality and validation from a major partner is likely to weigh on near-term sentiment, though no termination penalties apply and prior payments are non-refundable.
CMCO reported Q2 FY27 net sales of $539.3M (+107% Y/Y) and Adjusted EPS of $0.61, beating consensus of ~$518.6M and $0.38 respectively, with Adjusted EBITDA margin up 520 bps to 20.6%. Management raised FY27 guidance for net sales, Adjusted EBITDA, and Adjusted EPS, and the stock jumped double digits on the release, a clear positive near-term sentiment driver.
Q3 2026 results beat; full-year revenue and cash guidance raised
OmniAb reported Q3 2026 revenue of $4.0M vs $2.2M a year ago and a narrower net loss of $0.12/share, then raised FY2026 revenue guidance to $35-39M (from $32-36M) and lifted year-end cash outlook to $53-57M. The beat-and-raise reinforces the durability of the licensing/royalty model and is a positive near-term signal, though the report is now nearly two weeks old and largely digested.
On Oct. 28, 2026, S&P raised Aeromexico's issuer credit rating to BB- from B+ and its secured notes to BB, citing resilient profitability and cash generation. The upgrade lowers perceived credit risk and could support bond and equity sentiment, though it is a modest one-notch move.
The Board declared a $0.07 per share dividend payable on or about November 16, 2026 to holders of record as of November 6, 2026. The imminent payment date is a minor, routine event with limited price impact but confirms continued capital returns.
DiaMedica announced enrollment of the 200th patient in the pivotal Phase 2/3 ReMEDy2 AIS trial, triggering the prespecified DSMB interim analysis for sample size re-estimation or futility. Results are expected in Q1 2027, so this is a de-risking/enrollment-progress signal rather than an immediate catalyst, but it keeps the key binary event on schedule and supports the clinical narrative.
$46M public equity offering closed, strengthening balance sheet
Teknova closed an underwritten offering of 9.2M shares at $5.00 for ~$42.9M net proceeds, boosting balance sheet flexibility and adding new institutional investors. While dilution is a consideration, the completed raise removes near-term financing overhang and supports execution.
Harbour BioMed announced China's NMPA approved batoclimab for anti-AChR antibody-positive generalized myasthenia gravis, the fourth drug approved from OmniAb's platform. This creates a potential future royalty stream, though management noted it is too early to determine pricing or royalty impact, limiting immediate financial effect.
Aeromexico posted record Q3 2026 revenue of ~$1.6B (+13.6% YoY) but operating income fell 25% and net income dropped 58% on a 57.6% fuel expense increase. Shares fell ~6% after the report as investors focused on elevated Q4 fuel costs and FX headwinds.
Effective Oct. 19, 2026, the U.S. DOT revoked restrictions that had limited Mexican carriers' Mexico-U.S. schedules, allowing Aeromexico to add frequencies and new routes. This expands growth opportunities in its key international market, a structural positive.
xPloration platform broadened to all customers; OmniTides introduced
OmniAb expanded commercial access to its xPloration single B-cell screening platform to all customers starting October 2026 and introduced the OmniTides peptide discovery offering at its Investor & Analyst Day. Management expects xPloration revenue of $2-3M in 2026, doubling in 2027 and again in 2028, supporting a longer-term growth narrative but with limited immediate revenue impact.
Korro announced dosing of the first cohort of healthy volunteers (2 mg/kg) in the global Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia in UCDs and HE, with UCD patient dosing expected in H1 2027 and interim data in H2 2027. Continued clinical execution supports the pipeline narrative and could provide modest positive sentiment.
Major shareholder Lightspeed Venture Partners sold 10,621 shares at an average price of $14.90 (~$158k) in a transaction dated September 11, 2026, disclosed via SEC filing. The size is small relative to the float and the disclosure is dated, so price impact is likely limited, but continued insider selling by a large holder is a mild overhang.
Eli Lilly ion-channel collaboration worth up to $370M milestones
OmniAb signed a global collaboration and license agreement with Eli Lilly for a new ion channel program, receiving an upfront payment plus eligibility for up to $370M in milestones and tiered royalties. Service revenue from the Lilly collaboration is expected to begin contributing in Q4 2026, providing a tangible near-term revenue catalyst and validating the platform.